Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.92
AGEN's Cash-to-Debt is ranked lower than
82% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. AGEN: 0.92 )
Ranked among companies with meaningful Cash-to-Debt only.
AGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24  Med: 1.42 Max: N/A
Current: 0.92
Equity-to-Asset 0.04
AGEN's Equity-to-Asset is ranked lower than
92% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AGEN: 0.04 )
Ranked among companies with meaningful Equity-to-Asset only.
AGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.33  Med: 0.04 Max: 0.92
Current: 0.04
-1.33
0.92
Piotroski F-Score: 2
Altman Z-Score: -5.54
Beneish M-Score: -3.35
WACC vs ROIC
16.96%
-619.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -212.91
AGEN's Operating Margin % is ranked lower than
60% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. AGEN: -212.91 )
Ranked among companies with meaningful Operating Margin % only.
AGEN' s Operating Margin % Range Over the Past 10 Years
Min: -1427.54  Med: -634.16 Max: -42.23
Current: -212.91
-1427.54
-42.23
Net Margin % -257.79
AGEN's Net Margin % is ranked lower than
62% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. AGEN: -257.79 )
Ranked among companies with meaningful Net Margin % only.
AGEN' s Net Margin % Range Over the Past 10 Years
Min: -1161.86  Med: -657.35 Max: -70.95
Current: -257.79
-1161.86
-70.95
ROE % -5587.09
AGEN's ROE % is ranked lower than
100% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. AGEN: -5587.09 )
Ranked among companies with meaningful ROE % only.
AGEN' s ROE % Range Over the Past 10 Years
Min: -5587.09  Med: -460.59 Max: -187.92
Current: -5587.09
-5587.09
-187.92
ROA % -58.95
AGEN's ROA % is ranked lower than
71% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. AGEN: -58.95 )
Ranked among companies with meaningful ROA % only.
AGEN' s ROA % Range Over the Past 10 Years
Min: -94.08  Med: -61.71 Max: -46.32
Current: -58.95
-94.08
-46.32
ROC (Joel Greenblatt) % -423.92
AGEN's ROC (Joel Greenblatt) % is ranked lower than
52% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. AGEN: -423.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -986.59  Med: -329.33 Max: -196.65
Current: -423.92
-986.59
-196.65
3-Year Revenue Growth Rate 36.40
AGEN's 3-Year Revenue Growth Rate is ranked higher than
83% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AGEN: 36.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AGEN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.9  Med: -5.4 Max: 96.1
Current: 36.4
-53.9
96.1
3-Year EBITDA Growth Rate 12.80
AGEN's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. AGEN: 12.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AGEN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.9  Med: -14.2 Max: 68.1
Current: 12.8
-50.9
68.1
3-Year EPS without NRI Growth Rate 9.20
AGEN's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. AGEN: 9.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.7  Med: -15.8 Max: 30.1
Current: 9.2
-39.7
30.1
GuruFocus has detected 5 Warning Signs with Agenus Inc $AGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AGEN's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AGEN Guru Trades in Q3 2016

Jim Simons Sold Out
Ken Fisher 62,549 sh (-32.84%)
Robert Bruce 155,677 sh (-33.33%)
» More
Q4 2016

AGEN Guru Trades in Q4 2016

Steven Cohen 31,400 sh (New)
Ken Fisher 62,549 sh (unchged)
Robert Bruce 155,677 sh (unchged)
» More
Q1 2017

AGEN Guru Trades in Q1 2017

Jim Simons 11,915 sh (New)
Ken Fisher 135,204 sh (+116.16%)
Robert Bruce 155,677 sh (unchged)
Steven Cohen Sold Out
» More
Q2 2017

AGEN Guru Trades in Q2 2017

Ken Fisher 135,204 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:MYOK, OTCPK:DTHR, NAS:ATRA, NAS:JNCE, NAS:SYRS, NAS:SELB, NAS:MCRB, NAS:GERN, NAS:BCRX, NAS:NSTG, NAS:BLCM, NAS:PDLI, NAS:PGNX, NAS:ASMB, LSE:PRTC, NAS:ABEO, NAS:CARA, NAS:BSTC, NAS:NERV, NAS:CCXI » details
Traded in other countries:AJ81.Germany,
Headquarter Location:USA
Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.

Agenus is an American biotechnology company. Its main target are immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharp & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs.

Ratios

vs
industry
vs
history
PB Ratio 56.11
AGEN's PB Ratio is ranked lower than
97% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AGEN: 56.11 )
Ranked among companies with meaningful PB Ratio only.
AGEN' s PB Ratio Range Over the Past 10 Years
Min: 2.51  Med: 7.57 Max: 56.11
Current: 56.11
2.51
56.11
PS Ratio 10.54
AGEN's PS Ratio is ranked higher than
58% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. AGEN: 10.54 )
Ranked among companies with meaningful PS Ratio only.
AGEN' s PS Ratio Range Over the Past 10 Years
Min: 4.6  Med: 24.01 Max: 144.63
Current: 10.54
4.6
144.63
EV-to-EBIT -5.51
AGEN's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AGEN: -5.51 )
Ranked among companies with meaningful EV-to-EBIT only.
AGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.6  Med: -4.6 Max: -1.4
Current: -5.51
-26.6
-1.4
EV-to-EBITDA -5.84
AGEN's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AGEN: -5.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.9  Med: -5.1 Max: -1.6
Current: -5.84
-41.9
-1.6
Current Ratio 3.79
AGEN's Current Ratio is ranked lower than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AGEN: 3.79 )
Ranked among companies with meaningful Current Ratio only.
AGEN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 4.71 Max: 42.49
Current: 3.79
0.64
42.49
Quick Ratio 3.79
AGEN's Quick Ratio is ranked higher than
50% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AGEN: 3.79 )
Ranked among companies with meaningful Quick Ratio only.
AGEN' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 4.71 Max: 42.49
Current: 3.79
0.64
42.49
Days Sales Outstanding 56.76
AGEN's Days Sales Outstanding is ranked higher than
57% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. AGEN: 56.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.12  Med: 20.97 Max: 183.56
Current: 56.76
0.12
183.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -34.20
AGEN's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AGEN: -34.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -52  Med: -22.2 Max: -1.5
Current: -34.2
-52
-1.5

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.44
AGEN's Price-to-Median-PS-Value is ranked higher than
86% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. AGEN: 0.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.31 Max: 117.31
Current: 0.44
0.24
117.31
Earnings Yield (Greenblatt) % -18.15
AGEN's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AGEN: -18.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -70.4  Med: -21.6 Max: -3.8
Current: -18.15
-70.4
-3.8

More Statistics

Revenue (TTM) (Mil) $43.57
EPS (TTM) $ -1.28
Beta2.58
Short Percentage of Float14.92%
52-Week Range $3.20 - 7.49
Shares Outstanding (Mil)99.12

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 46 16 10
EPS ($) -1.41 -1.62 -1.58
EPS without NRI ($) -1.41 -1.62 -1.58
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AGEN

Headlines

Articles On GuruFocus.com
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine S Jun 21 2017 
Positive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant Jun 21 2017 
Agenus to Webcast Annual Meeting of Stockholders Jun 21 2017 
Agenus' anti-CTLA-4 antibody shows strong safety and tolerability Jun 05 2017 
Agenus to Participate at Two Upcoming Conferences in New York City: Jefferies Healthcare and JMP Sec Jun 01 2017 
Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting May 22 2017 
Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update May 04 2017 
Agenus to Report First Quarter 2017 Financial Results on May 4, 2017; Conference Call to Follow Apr 27 2017 
Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins Apr 20 2017 
Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax™ Apr 05 2017 

More From Other Websites
New Strong Buy Stocks for July 20th Jul 20 2017
uniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher Jul 20 2017
Agenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session Jul 19 2017
Eiger BioPharmaceuticals (EIGR) Rises: Stock Climbs 24% Jul 17 2017
3 Stocks That Are Ridiculously Cheap Right Now Jul 16 2017
Alexion Reportedly Being Investigated by HHS, Shares Slip Jul 07 2017
VIVUS Settles with Teva on Weight Management Drug Generic Jul 06 2017
Geron Stock Up Almost 40% So Far This Year After '16 Decline Jul 05 2017
Is the Options Market Predicting a Spike in Agenus (AGEN) Stock? Jul 03 2017
Better Buy: Agenus Inc. vs. Kite Pharma Jul 02 2017
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine... Jun 21 2017
Positive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant Jun 21 2017
Agenus to Webcast Annual Meeting of Stockholders Jun 21 2017
Agenus (AGEN) Looks Good: Stock Moves Up 9.6% in Session Jun 21 2017
Agenus, Inc. breached its 50 day moving average in a Bullish Manner : AGEN-US : June 21, 2017 Jun 21 2017
Today's Research Reports on Stocks to Watch: Agenus and Impax Laboratories Jun 21 2017
Agenus (AGEN) Down 15.7% Since Earnings Report: Can It Rebound? Jun 08 2017
3 Stocks With Exelixis-Like Return Potential Jun 05 2017
Agenus' anti-CTLA-4 antibody shows strong safety and tolerability Jun 05 2017
Agenus to Participate at Two Upcoming Conferences in New York City: Jefferies Healthcare and JMP... Jun 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}